Answers are grounded in this paper and cite their sources.
Glucocorticoids (GCs) induce apoptosis in leukocytes and remain a cornerstone of acute lymphoblastic leukemia (ALL) therapy, though resistance and toxicity remain problems. GEB052, a previously published Boolean model of the glucocorticoid receptor (GR) and its connected proteins, input (GC) and outputs (cell death and inflammation), generated insight into glucocorticoid resistance. The present study improved the model's predictive capacity through the inclusion of 26 microRNAs (miRs), resulting in a new model: GAO078 (78 nodes, 274 edges). GAO078 demonstrated improved correct prediction rates compared with GEB052, while dependency matrix and DRUGSURV analyses, together with laboratory validation, identified signal transducer and activator of transcription 5B (STAT5B) as an important level of control linked to GCs and apoptosis. The tyrosine kinase inhibitor dasatinib (DAS), which targets STAT5B and conventionally targets break point cluster (BCR)‑Abelson tyrosine kinase gene (ABL), was shown in ALL cell lines to have selective efficacy for GC‑resistant cells. Notably, cytotoxicity was demonstrated for BCR‑ABL‑negative leukemic cells, suggesting the potential for the use of DAS in this type of leukemia cells, upon further testing. GAO078 model analysis also identified miR‑27a, miR‑20a and miR‑9 to feature frequently and have clinical significance. Laboratory analysis of dexamethasone/DAS‑treated ALL cells showed an increase in the expression of these miRs. All three miRs are predicted to target nuclear receptor coactivators and corepressors; therefore, the outcome on nuclear receptor action could be a balance between multiple, complex networks. The findings of the present study demonstrate the significance of GR signaling and microRNA crosstalk in the determination of cell fate and emphasize the value of a systems biology approach in helping to identify routes towards reducing GC resistance and potentially improving future leukemia treatment.
No takes yet. Share an insight, caveat, or question.
Othman et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: